| Paper # |
Title of Paper |
Name of Presenter |
| 1 |
The prognostic importance of pathologic fracture in limb salvage surgery for primary bone sarcoma of the extremities |
Joseph Kendal, MD, FRCSC |
| 2 |
Surgical staging of osteosarcoma: does incorporation of chemotherapy response improve prediction of local recurrence? |
Zachary Burke, MD |
| 3 |
Biologic reconstruction with distraction osteogenesis in osseous sarcomas: A prospective analysis |
Anthony Bozzo, MD |
| 4 |
Reverse total shoulder arthroplasty demonstrates improved functional outcomes over hemiarthroplasty following proximal humerus replacement: long-term results of 170 cemented endoprosthetic reconstructions for tumors of the upper extremity |
Lauren E. Wessel, MD |
| 5 |
Should larger stem diameter be prioritized over cement mantle thickness? An analysis of risks for failure in cemented endoprostheses with minimum five-year |
Joseph Ippolito, MD |
| 6 |
How do the outcomes of radiation associated pelvic and sacral bone sarcomas compare to primary osteosarcomas following surgical resection? |
Alexander Leandros Lazarides, MD |
| 7 |
The Use of Deep Learning for Necrosis Assessment in Patients with Osteosarcoma |
Christa L. LiBrizzi, MD |
| 8 |
Bone marrow aspiration and biopsy in the initial staging of extraskeletal Ewing sarcoma |
Brian Wahlig |
| 9 |
Serum Metal Ion Concentrations in the Setting of an Oncologic Endoprosthesis: Is There Cause for Concern? |
Matthew T. Houdek, MD |
| 10 |
Surgical Management of Chondrosarcoma of long bones utilizing a pre-operative radiologic aggressiveness score? |
Zachary Burke, MD |
| 11 |
Usage Trends and Safety Profile of Recombinant Human Bone Morphogenetic Protein-2 for Spinal Column Tumor Surgery: A National Matched Cohort Analysis |
Noe C. Trevino |
| 12 |
Re-evaluating the Work Up of Bone Lesions of Unknown Etiology: A Systematic Analysis |
Harrison Miner, MD |
| 13 |
Functional Outcomes of Pediatric and Adult Patients after Endoprosthetic Reconstruction of Lower Extremity Tumors |
Tina H. Tran, BS |
| 14 |
Mapping The Course of Recovery Following Limb Salvage Surgery for Soft Tissue Sarcoma of the Extremities |
Alexander Leondros Lazarides, MD |
| 15 |
The Sarcoma-Specific Quality of Life Study (SARC-QoL): Identifying key domains of Health-Related Quality of Life in adult patients with extremity soft tissue sarcoma |
Krista Goulding MD, FRCSC, MPH |
| 16 |
Utilization of Mental Health Referrals for Symptoms of Anxiety and Depression in Patients with Sarcoma |
Meredith Bartelstein, MD |
| 17 |
Targeting immune checkpoint blockade molecule B7-H3 using CAR T cells as adjuvant therapy in chordoma |
David Osei-Hwedieh, MD, PhD |
| 18 |
SKP2 knockout in Rb1/p53 deficient transgenic mouse models of osteosarcoma improves survival via induction of macrophage infiltration |
Alexander Ferrena |
| 19 |
DNMT3B is a novel target in high grade chondrosarcoma |
Alex Michael Hollenberg |
| 20 |
Expression of Angiogenesis Markers HSP70, HSP90, VEGF and pERK1/2 in Both Components of Dedifferentiated Chondrosarcomas |
Rebekah Belayneh, MD |
| 21 |
Intra-Articular Injections of AMB-05X, A Potent, Selective, Human Monoclonal Antibody Against Colony Stimulating Factor 1 Receptor for the Treatment of Tenosynovial Giant Cell Tumor |
Thomas J. Scharschmidt, MD |
| 22 |
Use of Small Molecule STING Agonist Immunotherapy for Canine Soft Tissue Sarcoma: A Cross-Species Analysis |
Michael Monument, MD |
| 23 |
Improvement in Survival After Treatment for Metastatic Bone Disease: An International Trend-Analysis |
Davis Lane Rogers, MD |
| 24 |
Indications and longevity of endoprosthetic reconstructions for patients with metastatic bone disease |
Joseph Kendal, MD, FRCSC |
| 25 |
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer |
Michael Monument, MD |
| 26 |
Locking Plate Augmentation of Polymethylmethacrylate-Filled Distal Femur Defects |
Harrison Robert Ferlauto, MD |
| 27 |
Comparison of Carbon Fiber and Titanium Intramedullary Nails In Orthopaedic Oncology |
Santiago Lozano-Calderon, MD, PhD |
| 28 |
The Musculoskeletal Tumor Registry: Progress and Priorities Update for 2022 |
Adam S. Levin, MD |
| 29 |
Development Of The Metastatic Bone Disease Module Within The American Academy Of Orthopaedic Surgeons Musculoskeletal Tumor Registry |
George T. Calvert, MD |
| 30 |
Establishing Data Elements for the Musculoskeletal Tumor Registry Sarcoma Module |
Adam S. Levin, MD |
| 31 |
Minimally Invasive Percutaneous Screw Fixation in Painful Pelvic Lesion Caused by Metastatic Cancer |
Rui Yang, MD |
| 32 |
Treatment of oligometastases: indications and results in 156 cases |
Pietro Ruggieri, MD |
| 33 |
Metastatic Bone Disease at Diagnosis is Associated with Increased Rate of Body Mass Index Loss and Worse Survival in Clear Cell Renal Cell Carcinoma |
Jon-Luc Poirier, BA |
| 34 |
Clinical Outcomes of Patients Treated with Carbon-Fiber Nails for Oncologic Indications in Long-Bones: An International Multi-Institutional Study |
Santiago A. Lozano-Calderon, MD, PhD |
| 35 |
A cost effectiveness analysis of elective versus emergent surgery for patients with metastatic bone disease |
Joseph Kendal, MD, FRCSC |
| 36 |
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: Final results from the phase 3 ENLIVEN study |
John H. Healey, MD, FACS |
| 37 |
Defining minimally important differences in functional outcomes for musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction |
Aaron M. Gazendam, MD |
| 38 |
Predictors of functional recovery among musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction |
Aaron M. Gazendam, MD
|
| 39 |
Neoadjuvant chemotherapy and endoprosthetic reconstruction for lower extremity sarcomas: Does timing impact complication rates? |
Aaron M. Gazendam, MD
|
| 40 |
Opioid use in musculoskeletal oncology |
Aaron M. Gazendam, MD |
| 41 |
Risk factors for all-cause early re-operations in patients undergoing tumor resection and endoprosthetic reconstruction: a secondary analysis from the PARITY trial |
Joseph Kendal, MD, FRCSC |
| 42 |
Surveillance AFter Extremity Tumor surgerY (SAFETY): Results of the Pilot International Randomized Controlled Trial |
Michelle Ghert, MD, FRCSC |
| 43 |
Gender Disparity within the Musculoskeletal Tumor Society: Does it exist? |
Brian Batko, MD |
| 44 |
Epidemiology And Survival Factors For Sarcoma Patients In Minority Populations: A Seer-Retrospective Study |
Victoria Dahl |
| 45 |
The Work Relative Value Unit System May Not Be the Optimal Measure of an Orthopaedic Oncologist's Productivity |
Tae Won Benjamin Kim, MD |
| 46 |
Using the Social Vulnerability Index to Assess Social Determinants of Bone Cancer Care & Prognosis in the United States |
David Fei-Zhang, BA |
| 47 |
Patient engagement in sarcoma research: benefits, challenges, importance, and implications |
Michelle Ghert, MD, FRCSC |
| 48 |
MRI based navigated cryosurgery of extra-abdominal desmoid tumors using skin fiducials markers |
Ortal Segal, MD
|
| 49 |
Development of a Prognostic Nomogram to Predict 30-day Readmission in Localized Soft Tissue Sarcomas of the Extremity |
Meena Bedi, MD |
| 50 |
Outcome of Multidisciplinary Treatment of Merkel Cell Carcinoma of the Lower Extremity |
Samuel E. Broida, MD |
| 51 |
Predicting Diagnosis in Myxoid Soft Tissue Tumors: Performance of Radiomics vs. Radiologists |
Joshua M. Lawrenz, MD |
| 52 |
First-in-human Clinical Trial Results of a Small-Molecule Fluorophore Applied to Soft-Tissue Sarcomas |
Eric R Henderson, MD |
| 53 |
Clinical impact of whole-body MRI in the staging and surveillance of patients with myxoid liposarcoma: a 14-year single-center experience |
Robert Turcotte, MD |
| 54 |
MSTS Member Survey: Intra-Operative Peripheral Margins in Soft Tissue Sarcoma |
Lauren Zeitlinger, DO |
| 55 |
Do High- and Low-Risk Pediatric Rhabdomyosarcoma Survival Estimates Equalize 5 Years After Diagnosis? A Cause-specific Conditional Survival Analysis |
Benjamin J. Miller, MD, MS |
| 56 |
What factors differentiate early vs. late pulmonary metastases in soft tissue sarcoma of the extremities? A comparative cohort analysis |
Alexander Leandros Lazarides, MD |
| 57 |
Follow-up for patients with extremity soft tissue sarcoma: validation of a rational schedule. |
Maroun Rizkallah, MD |
